Question 1

Why is monitoring both the active drug and its metabolite important in pharmacotherapy?

Accepted Answer

Both the active drug and its metabolite contribute to the therapeutic effect, making their concentration monitoring crucial. In hepatic impairment, changes in liver function alter drug potency differently depending on which compound is more potent. If the drug is more potent than its metabolite, liver impairment increases drug activity due to higher drug concentrations. Conversely, if the metabolite is more potent, activity decreases due to reduced metabolite formation.

Question 2

How does hepatic impairment affect drug potency and metabolite formation?

Accepted Answer

Hepatic impairment alters liver function, which directly impacts drug potency. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity by elevating drug concentration levels. If the metabolite holds greater potency, diminished liver function reduces drug activity by hampering metabolite formation. The direction of effect depends on the relative potency of each compound.

Question 3

What are the two components of drug elimination in the body?

Accepted Answer

Drug elimination consists of two components: the fraction excreted unchanged in urine and the fraction metabolized by the liver. The metabolized fraction can be estimated from the equation 1 - fe, where fe represents the fraction excreted unchanged. Total body clearance can be calculated assuming metabolism occurs in the liver and unchanged drug is excreted renally.

Question 4

Why are drugs with a higher fraction metabolized more sensitive to liver disease?

Accepted Answer

Drugs with a higher fraction of metabolized compounds rely heavily on hepatic metabolism for elimination. Because they depend more on liver function for drug clearance, changes in liver function significantly impact their pharmacokinetics. Hepatic impairment can substantially alter drug concentrations in these patients, potentially necessitating dose adjustments or alternative therapeutic strategies.

Question 5

How is the fraction metabolized estimated from drug elimination data?

Accepted Answer

The fraction metabolized is typically estimated using the equation 1 - fe, where fe is the fraction excreted unchanged. This calculation assumes that the remaining fraction not excreted unchanged must be metabolized by the liver. Under the assumption that metabolism occurs in the liver and unchanged drug is excreted in urine, this relationship allows clinicians to determine how dependent a drug is on hepatic metabolism.

Question 6

What relationship exists between hepatic clearance and total body clearance?

Accepted Answer

The extent of a metabolized fraction can be inferred from the ratio of hepatic clearance to total body clearance. This relationship reveals how much of the drug's elimination depends on liver metabolism versus other routes. Drugs with high hepatic clearance relative to total body clearance are more significantly impacted by changes in liver function, requiring careful monitoring in patients with hepatic dysfunction.

Question 7

What clinical considerations apply when managing patients with hepatic dysfunction?

Accepted Answer

Vigilant monitoring of drug and metabolite concentrations is essential in managing patients with hepatic dysfunction to ensure optimal therapeutic outcomes while minimizing adverse effects. Hepatic impairment can substantially impact pharmacokinetics of drugs dependent on liver metabolism. Clinicians must assess liver function and consider dose adjustments or alternative therapeutic strategies based on the drug's reliance on hepatic metabolism and the relative potency of active and metabolite forms.

Wpływ choroby wątroby na farmakokinetykę: substancja czynna, metabolit i frakcja metabolizowana leku

Browse More Videos